



## **Nyxoah Announces Participation in the Piper Sandler 33<sup>rd</sup> Annual Virtual Healthcare Conference**

Mont-Saint-Guibert, Belgium. – November 12, 2021, 10:30 pm CET / 4:30 pm ET - Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Olivier Taelman, Chief Executive Officer, will participate at the Piper Sandler 33<sup>rd</sup> Annual Virtual Healthcare Conference on from November 22 to December 2, 2021.

A webcast of the Company’s fireside chat will be available on the Company’s investor relations website at <https://investors.nyxoah.com/>

Nyxoah is participating in investor 1x1 meetings, which can be requested through Piper Sandler.

### **About Nyxoah**

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio<sup>®</sup> system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio<sup>®</sup> system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE-Mark indication approval to treat Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

For more information, please visit <http://www.nyxoah.com/>

**Caution** – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

### **Contacts:**

#### **Nyxoah**

Jeremy Feffer, VP IR and Corporate Communications

[jeremy.feffer@nyxoah.com](mailto:jeremy.feffer@nyxoah.com)

+1 917 749 1494

#### **Gilmartin Group**

Vivian Cervantes

[IR@nyxoah.com](mailto:IR@nyxoah.com)